Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Hold” from Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received an average recommendation of “Hold” from the eleven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $4.79.

MRNS has been the topic of a number of recent analyst reports. StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a report on Sunday. They set a “sell” rating on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Suvretta Capital Management LLC increased its stake in Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. Beryl Capital Management LLC bought a new position in shares of Marinus Pharmaceuticals in the fourth quarter worth approximately $2,262,000. abrdn plc raised its stake in Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares in the last quarter. Finally, Woodline Partners LP raised its stake in Marinus Pharmaceuticals by 84.7% in the fourth quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock valued at $1,250,000 after purchasing an additional 1,071,410 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Trading Down 0.2 %

Shares of MRNS opened at $0.55 on Thursday. The stock has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $10.50. The firm has a fifty day simple moving average of $0.52 and a 200 day simple moving average of $0.82.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.